Abstract
Alzheimer’s disease (AD) is one of the most threatening diseases affecting the aged with high incidence. Though AD has been defined for more than 100 years, it is still incurable. The drugs clinically used for the treatment of this disease, such as acetylcholinesterase inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonist, can only provide a limited therapeutic effect. The need of effective drugs has stimulated the search for new compounds with potential clinical utility. Natural products are rich and unexplored sources for discovering novel leading compounds. Currently, a great number of natural products have been found possessing anti-AD property counteracting different etiological factors of AD. This review will give an update demonstration on the novel anti-AD natural products and their derivatives/analogues, which have been divided into five subgroups according to their different action mechanisms: AChEIs, antioxidants, neuroprotective agents, monoamine oxidase (MAO) inhibitors, and tau hyperphosphorylation inhibitors. We put special emphasis on the findings in the past 5 years. Besides, the drug design strategy as well as the structure-activity relationship of the relevant compounds is also discussed when it is possible.
Keywords: Acetylcholinesterase inhibitor, Alzheimer’s disease, antioxidant, monoamine oxidase inhibitor, natural product, neuroprotection
Mini-Reviews in Medicinal Chemistry
Title:Current Progresses of Novel Natural Products and Their Derivatives/ Analogs as Anti-Alzheimer Candidates: an Update
Volume: 13 Issue: 6
Author(s): Lei Fang, Shaohua Gou, Xubin Fang, Lin Cheng and Christian Fleck
Affiliation:
Keywords: Acetylcholinesterase inhibitor, Alzheimer’s disease, antioxidant, monoamine oxidase inhibitor, natural product, neuroprotection
Abstract: Alzheimer’s disease (AD) is one of the most threatening diseases affecting the aged with high incidence. Though AD has been defined for more than 100 years, it is still incurable. The drugs clinically used for the treatment of this disease, such as acetylcholinesterase inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonist, can only provide a limited therapeutic effect. The need of effective drugs has stimulated the search for new compounds with potential clinical utility. Natural products are rich and unexplored sources for discovering novel leading compounds. Currently, a great number of natural products have been found possessing anti-AD property counteracting different etiological factors of AD. This review will give an update demonstration on the novel anti-AD natural products and their derivatives/analogues, which have been divided into five subgroups according to their different action mechanisms: AChEIs, antioxidants, neuroprotective agents, monoamine oxidase (MAO) inhibitors, and tau hyperphosphorylation inhibitors. We put special emphasis on the findings in the past 5 years. Besides, the drug design strategy as well as the structure-activity relationship of the relevant compounds is also discussed when it is possible.
Export Options
About this article
Cite this article as:
Fang Lei, Gou Shaohua, Fang Xubin, Cheng Lin and Fleck Christian, Current Progresses of Novel Natural Products and Their Derivatives/ Analogs as Anti-Alzheimer Candidates: an Update, Mini-Reviews in Medicinal Chemistry 2013; 13 (6) . https://dx.doi.org/10.2174/1389557511313060009
DOI https://dx.doi.org/10.2174/1389557511313060009 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Delivery Technologies and Stem Cells for Tissue Repair and Regeneration
Current Pharmaceutical Biotechnology Importance of Zebrafish as an Efficient Research Model for the Screening of Novel Therapeutics in Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Anticholinesterase Activity of Three Local Food Spices and Their Anti-Alzheimer Application
Current Nutraceuticals Memory Enhancing Effect of Black Pepper in the AlCl3 Induced Neurotoxicity Mouse Model is Mediated Through Its Active Component Chavicine
Current Pharmaceutical Biotechnology The Antidepressant-like Effects of Estrogen-mediated Ghrelin
Current Neuropharmacology Stage-Dependent Agreement between Cerebrospinal Fluid Proteins and FDG-PET Findings in Alzheimer's Disease
Current Alzheimer Research Coumarin-1,2,3-triazole Hybrid Molecules: An Emerging Scaffold for Combating Drug Resistance
Current Topics in Medicinal Chemistry Amyotrophic Lateral Sclerosis: From Research to Therapeutic Attempts and Therapeutic Perspectives
Current Medicinal Chemistry Are Circulating Monocytes as Microglia Orthologues Appropriate Biomarker Targets for Neuronal Diseases? (Supplementry Table)
Central Nervous System Agents in Medicinal Chemistry Differences in Relative Levels of 88 microRNAs in Various Regions of the Normal Adult Human Brain
MicroRNA Transcranial Magnetic Stimulation of Degenerating Brain: A Comparison of Normal Aging, Alzheimer’s, Parkinson’s and Huntington's Disease
Current Alzheimer Research Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation
Current Alzheimer Research Editorial (Thematic Selection: Critical Analyses of Mechanism-Based Therapies Against Parkinson’s Disease: Concepts and Perspectives)
Current Neuropharmacology Editorial:Genomics and Epigenomics of Tumor and Aging Cells
Current Genomics P-gp Transporter and its Role in Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment
Current Pharmaceutical Design Commentary (Research Highlights)
CNS & Neurological Disorders - Drug Targets Physically Cross-linked Hydrogels of β -cyclodextrin Polymer and Poly(ethylene glycol)-cholesterol as Delivery Systems for Macromolecules and Small Drug Molecules
Current Drug Delivery Editorial (Thematic Issue: MiRNAcles in the Brain: What to Wish and What to Fear)
CNS & Neurological Disorders - Drug Targets General Aspects of Metal Toxicity
Current Medicinal Chemistry